Loading...
DICE logo

DICE Therapeutics, Inc.NasdaqGM:DICE Stock Report

Market Cap US$2.3b
Share Price
n/a
1Y131.2%
7D0.2%
1D0.06%
Portfolio Value
​
View

DICE Therapeutics, Inc.

NasdaqGM:DICE Stock Report

Market Cap: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

DICE Therapeutics (DICE) Stock Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. More details

DICE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 22.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

DICE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,321 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
439,321 investors already sharing narratives
View all narratives

DICE Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for DICE Therapeutics
Historical stock prices
Current Share PriceUS$47.55
52 Week HighUS$47.90
52 Week LowUS$15.08
Beta0
1 Month Change1.67%
3 Month Change32.90%
1 Year Change131.16%
3 Year Changen/a
5 Year Changen/a
Change since IPO28.90%

Recent News & Updates

Analysis Article • May 14

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, DICE Therapeutics...

Recent updates

Analysis Article • May 14

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, DICE Therapeutics...
Seeking Alpha • Oct 11

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Top-line results from a phase 1 trial of DICE Therapeutics' (NASDAQ:DICE) DC-806 for psoriasis showed the candidate met its proof-of-concept goal and was biologically active. Shares are up 71% in premarket trading. Data also showed DC-806 was well tolerated with an excellent safety profile. The placebo-controlled portion enrolled eight psoriasis patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. After four weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group. DICE (DICE) now plans to move DC-806, an oral IL-17 antagonist, into a dose-ranging phase 2b clinical trial. The company anticipates submitting an IND application with the US FDA in 1H 2023 and begin phase 2b at that time. Seeking Alpha's Quant Rating views DICE as a hold with high marks for growth and momentum.
Analysis Article • Sep 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

DICE Therapeutics GAAP EPS of -$0.58

DICE Therapeutics press release (NASDAQ:DICE): Q2 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities totaled $282.2 million at June 30, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones.
Seeking Alpha • Jul 18

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

HC Wainwright has initiated coverage of DICE Therapeutics (NASDAQ:DICE) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling libraries (DELs)." The firm has a $40 price target (~151% upside based on Friday's close). Analyst Emily Bodnar said that DELSCAPE can "identify selective binders by producing small, targeted DELs which has led to hundreds to tens of thousands of hits against difficult PPI targets." The company's lead candidate DC-806, a pill that targets IL-17, is being eyed for psoriasis. It is currently in phase 1. Bodnar conceded that although there are several IL-17-targeted biologics for psoriasis and related indications, there is only one approved that is a pill, Amgen's (AMGN) Otezla (apremilast). She noted that though Otezla has a PASI-75 score (efficacy) of only ~30%, the drug has more than $2B in annual sales. A full data readout from the phase 1 trial is expected this quarter, and if it is positive, the stock could see significant upside, Bodnar wrote.

Shareholder Returns

DICEUS PharmaceuticalsUS Market
7D0.2%-3.4%-1.0%
1Y131.2%44.7%14.1%

Return vs Industry: DICE exceeded the US Pharmaceuticals industry which returned 7.3% over the past year.

Return vs Market: DICE exceeded the US Market which returned 4.8% over the past year.

Price Volatility

Is DICE's price volatile compared to industry and market?
DICE volatility
DICE Average Weekly Movement11.3%
Pharmaceuticals Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: DICE's share price has been volatile over the past 3 months.

Volatility Over Time: DICE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201381J. Judicewww.dicetherapeutics.com

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications.

DICE Therapeutics, Inc. Fundamentals Summary

How do DICE Therapeutics's earnings and revenue compare to its market cap?
DICE fundamental statistics
Market capUS$2.27b
Earnings (TTM)-US$104.24m
Revenue (TTM)n/a
0.0x
P/S Ratio
-21.8x
P/E Ratio

Is DICE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DICE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$62.56m
Gross Profit-US$62.56m
Other ExpensesUS$41.68m
Earnings-US$104.24m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DICE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/10 11:15
End of Day Share Price 2023/08/08 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DICE Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.